<DOC>
	<DOCNO>NCT00535314</DOCNO>
	<brief_summary>The primary purpose study determine proportion patient without progression 6-months patient unresectable Stage III Stage IV melanoma take RTA 402 .</brief_summary>
	<brief_title>Study Two Dose Levels RTA 402 Patients With Advanced Malignant Melanoma</brief_title>
	<detailed_description>This phase II , open label , randomize study patient unresectable Stage III Stage IV malignant melanoma . Patients randomly assign two different dos RTA 402 administer orally daily 28 consecutive day , 18 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Greater equal 18 year age Confirmed diagnosis malignant ( unresectable Stage III Stage IV ) melanoma Measurable disease , define least 1 lesion measure equal 20 mm conventional technique , equal 10 mm spiral CT scan , cutaneous lesion great equal 10 mm caliper . May receive 1 prior chemotherapy metastatic disease . May receive prior vaccine therapy adjuvant setting . May receive cytokine therapy adjuvant set and/or 1 prior cytokine therapy metastatic disease . ECOG performance 01 Must adequate liver renal function document laboratory test result . Must adequate bone marrow function document lab result . Must complete prior chemotherapy , immunotherapy , radiation , biological , investigational cancer therapy least 4 week prior start study , recover acute side effect . Patients receive mitomycin C nitrosoureas must 6 week last administration chemotherapy . Man woman must agree practice effective contraception study least 2 month last dose RTA 402 . Must life expectancy 3 month . Must willing able sign inform consent form . Must willing able take document oral dos RTA 402 . May receive 1 prior chemotherapy . May receive 1 prior cytokine therapy metastatic disease . Diagnosis ocular melanoma . Inability swallow tablet capsule Symptomatic malabsorptive disorder ( eg , Crohn 's Disease ) , removal either terminal ileus 2/3 small intestine . Active brain metastasis primary central nervous system malignancy ; patient previously treat brain metastasis may include provided requirement steroid evidence progression great equal 8 week treatment . Active second malignancy . Weight loss great equal 10 % 6 week prior dose Pregnant breast feed Clinically significant illness could compromise participation study , include : uncontrolled diabetes ; active uncontrolled infection ; acute chronic liver disease ; confirm diagnosis HIV infection ; uncontrolled hypertension , symptomatic congestive heart failure , unstable angina pectoris , myocardial infarction within last 6 month , uncontrolled cardiac arrhythmia . Psychiatric illness would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Melanoma</keyword>
</DOC>